Pharmaids Pharmaceuticals (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Pharmaids Pharmaceuticals Limited |
|||
|
Price: ₹60.90 | ||
| 52 Week Low: ₹31.90 52 Week High: ₹87.46 |
|||
| Market Capital: 61.47 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Pharmaids Pharmaceuticals Share Price Target For 2024
- 1.1.1: Pharmaids Pharmaceuticals Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Pharmaids Pharmaceuticals Share Price Target For 2025
- 1.2.1: Pharmaids Pharmaceuticals Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Pharmaids Pharmaceuticals Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Pharmaids Pharmaceuticals Financial Performance
- 3.0.1: Is Pharmaids Pharmaceuticals A Good Buy For Long Term?
To predict the Pharmaids Pharmaceuticals's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Pharmaids Pharmaceuticals Share Price Target For 2024
The line chart displays the monthly closing prices of Pharmaids Pharmaceuticals with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Pharmaids Pharmaceuticals shares in 2024, see the table below.
Pharmaids Pharmaceuticals Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 65.2 (+7.06%) | Price Action: 08 Jan 2024 High |
| 2024 Target 2 | 64.39 (+5.73%) | Price Action: 02 Dec 2024 Low |
| 2024 Target 1 | 63.49 (+4.25%) | Price Action: 22 Apr 2024 High |
| Current Price | 60.90 | Pharmaids Pharmaceuticals's share price as of 26 Dec 2024 |
| Stop Loss 1 | 59.78 (-1.84%) | Price Action: 25 Apr 2024 Low |
| Stop Loss 2 | 59.15 (-2.88%) | Price Action: 04 Jan 2024 High |
| Stop Loss 3 | 58.53 (-3.9%) | Price Action: 13 Dec 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Pharmaids Pharmaceuticals is showing mixed momentum signals near key moving averages.
Key Technical Level: The 25-day moving average at ₹62.8 serves as the nearest technical reference point.
Historical Returns: 3-month: +55.36% | 6-month: +22.04% | 1-year: +25.1%
Pharmaids Pharmaceuticals Share Price Target For 2025
The line chart displays the monthly closing prices of Pharmaids Pharmaceuticals with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Pharmaids Pharmaceuticals shares in 2025, see the table below.
Pharmaids Pharmaceuticals Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 100.57 (+65.13%) | Fibonacci Extension Level 123.60% |
| 2025 Target 2 | 97.93 (+60.8%) | Price Action: Chart |
| 2025 Target 1 | 96.96 (+59.21%) | Fibonacci Extension Level 64.90% |
| Current Price | 60.90 | Pharmaids Pharmaceuticals's share price as of 26 Dec 2024 |
| Stop Loss 1 | 52.5 (-13.8%) | Price Action: 20 Mar 2024 Low |
| Stop Loss 2 | 51.83 (-14.9%) | Price Action: 21 Feb 2024 Low |
| Stop Loss 3 | 51.3 (-15.77%) | Price Action: 19 Mar 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Pharmaids Pharmaceuticals is currently trading at 52.2% of its 52-week range (₹31.9 - ₹87.46).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +25.1% | 3-year: +297% | 5-year: +1,132.79%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Pharmaids Pharmaceuticals Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹60.90 | ||
| 2024 | ₹65.65 | +7.79% | ₹66.63 |
| 2025 | ₹74.34 | +13.23% | ₹75.46 |
| 2026 | ₹87.76 | +18.05% | ₹95.94 |
| 2027 | ₹112.29 | +27.95% | ₹113.97 |
| 2028 | ₹137.46 | +22.41% | ₹139.52 |
| 2029 | ₹159.26 | +15.85% | ₹161.65 |
| 2030 | ₹156.82 | -1.53% | ₹166.63 |
| 2031 | ₹167.45 | +6.77% | ₹190.19 |
| 2032 | ₹198.58 | +18.59% | ₹213.75 |
| 2033 | ₹229.02 | +15.32% | ₹232.46 |
| 2034 | ₹252.87 | +10.41% | ₹256.66 |
| 2035 | ₹239.30 | -5.36% | ₹260.87 |
| 2036 | ₹247.14 | +3.27% | ₹284.43 |
| 2037 | ₹284.87 | +15.26% | ₹307.99 |
| 2038 | ₹320.58 | +12.53% | ₹325.39 |
| 2039 | ₹311.11 | -2.95% | ₹331.55 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Pharmaids Pharmaceuticals Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 61.47 Crore | Market valuation of Pharmaids Pharmaceuticals's shares. |
| Net Income (TTM) | -7.55 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
Is Pharmaids Pharmaceuticals A Good Buy For Long Term?
Pharmaids Pharmaceuticals, with consistent positive returns across various timeframes, presents a compelling investment opportunity for long-term investors. Its impressive past performance, particularly in the past 12 months and 5 years, suggests strong growth potential. While past returns do not guarantee future performance, the company's consistent growth trajectory warrants consideration for long-term portfolio inclusion.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
